CSL Limited Annual Report 2021/22 16 3 Our Performance and Strategy Business performance highlights Focus • Remained focused on delivering on our promise to patients and public health during an unprecedented time of uncertainty. • US$17.8 million supporting product access across the world.* • US$50 million in global community investment across our strategic areas of support. Innovation • Research and development (R&D) investment of US$1.16 billion.* • Etranacogene dezaparvovec (Haemophilia B gene therapy) primary end point achieved in HOPE-B study with MAA (EU) and BLA (US) submitted. • Garadacimab Phase III study enrolment completed for HAE. • CSL112 (currently in Phase III for cardiovascular disease) continues to progress with over 80% enrolment. • Phase II study for an adjuvanted QIV cell-based influenza vaccine completed. • Government funding for new biotech start-up incubator partnership between CSL, WEHI and University of Melbourne. • Achieved 24 product registrations or new indications across the globe. Efficiency and reliable supply • Ongoing investment in major capital projects at all manufacturing sites to support future growth. • In 2021/22, 27 new plasma collection centres opened. • New plasmapheresis platform approved. • Participated in 406 regulatory inspections of our manufacturing facilities and plasma collection centres.* • 135 million influenza vaccine doses distributed by CSL Seqirus. • Fill and finish capacity expansion projects completed at Holly Springs and Liverpool for influenza vaccines. Sustainable growth • Revenue up 3% at constant currency. • Significant growth in plasma collections. • Strong performance by HIZENTRA®, our market leading subcutaneous immunoglobulin product with sales up 20%. • KCENTRA®, our peri-operative bleeding product, grew 18% as hospital demand returned to pre-pandemic levels. • CSL Seqirus revenue up 13% at constant currency driven by strong growth in seasonal influenza vaccines and product differentiation. • US$9.9 billion distributed in supplier payments, employee wages and benefits, shareholder returns, government taxes and community contributions.* • Announced Science Based Targets initiative aligned emissions reduction targets. Digital transformation • Enhanced CSL Plasma Donor App with new functionality. • Progression of the converged enterprise network strategy across the organisation. • Initiation of our next generation Donation Management System. People and culture • Achieved 77.9% employee engagement* score, an increase on the previous year. • 44% female representation at Board level, 61% female across the Group.* • Established early career programs for STEM talent around the globe to build our future talent pipeline. • CSL named among America’s best employers by Forbes magazine and also recognized as one of Australia and New Zealand’s Best Places to Work by The Australian Financial Review. * Limited assurance by Ernst & Young. Patients and Public Health underpin everything we do
RkJQdWJsaXNoZXIy MjE2NDg3